Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Acquired by Nomura Asset Management Co. Ltd.

Nomura Asset Management Co. Ltd. increased its position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) by 25.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 36,925 shares of the company’s stock after acquiring an additional 7,496 shares during the quarter. Nomura Asset Management Co. Ltd. owned approximately 0.06% of Structure Therapeutics worth $1,001,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Point72 Asset Management L.P. boosted its holdings in Structure Therapeutics by 196.5% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,238,268 shares of the company’s stock valued at $54,348,000 after purchasing an additional 820,589 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in Structure Therapeutics by 18.0% in the third quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company’s stock valued at $173,623,000 after acquiring an additional 602,609 shares during the last quarter. Principal Financial Group Inc. grew its position in Structure Therapeutics by 230.0% in the third quarter. Principal Financial Group Inc. now owns 545,359 shares of the company’s stock worth $23,936,000 after acquiring an additional 380,115 shares during the period. Wellington Management Group LLP increased its stake in Structure Therapeutics by 2.9% during the third quarter. Wellington Management Group LLP now owns 7,769,771 shares of the company’s stock worth $341,015,000 after acquiring an additional 221,851 shares during the last quarter. Finally, Handelsbanken Fonder AB purchased a new stake in Structure Therapeutics in the fourth quarter valued at $4,475,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Stock Performance

NASDAQ GPCR opened at $16.95 on Thursday. The firm has a market cap of $971.96 million, a price-to-earnings ratio of -22.91 and a beta of -2.37. The firm has a 50 day simple moving average of $23.52 and a 200-day simple moving average of $30.73. Structure Therapeutics Inc. has a one year low of $15.31 and a one year high of $62.74.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.01. Equities analysts predict that Structure Therapeutics Inc. will post -0.82 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. William Blair initiated coverage on Structure Therapeutics in a report on Friday, February 28th. They set an “outperform” rating for the company. JMP Securities reaffirmed a “market outperform” rating and issued a $91.00 target price on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Stifel Nicolaus started coverage on shares of Structure Therapeutics in a research report on Wednesday, January 8th. They set a “buy” rating and a $50.00 price target for the company. Finally, HC Wainwright restated a “buy” rating and issued a $80.00 price objective on shares of Structure Therapeutics in a report on Thursday, December 19th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Structure Therapeutics has an average rating of “Buy” and a consensus target price of $81.29.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.